Emmanuel Lacroix

Emmanuel works with Arix Biosciences as Venture Partner, with a focus on sourcing, executing and managing investments within Europe.
He has a broad biotech background with expertise spanning venture capital, business development, and biotech or pharma strategy and operations.
Previously, Emmanuel was Vice President and Partner at UCB Ventures.
In that role, he sourced and led equity investments in Esobiotec, Walden Biosciences and Locanabio, as well as LP investments in other funds.
Earlier, as UCB’s Head of Business Development Neurology, he executed multiple licensing agreements and product acquisitions, plus equity investments in Lumos Pharma (Nasdaq : LUMO), and he led the launch and equity financing of UCB’s spin-out Syndesi Therapeutics (acquired by AbbVie).
He also held prior leadership positions in Sales and Global Marketing, at UCB, and in Discovery Research for Gene Editing at Cellectis SA. Emmanuel received an MBA from IMD (Switzerland), a Ph.D.
in Molecular Biology from ULB (Belgium) based on research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the ULG (Belgium).
He previously served on the Boards of Esobiotec, Walden Biosciences, Syndesi Therapeutics (acquired by AbbVie), and as observer, Locanabio and Lumos (Nasdaq : LUMO).